Has there been a decrease in the prevalence of mood disorders in HIV-seropositive individuals since the introduction of combination therapy?

European Psychiatry

Volumn 16, Issue 8, 2001, Pages 491-496

  Alciati, A ^a   Starace, F ^b,c   Scaramelli, B ^a   Campaniello, M ^a   Adriani, B ^b   Mellado, C ^a   Cargnel, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

Author keywords

Depression; HAART; HIV; Mood disorders; Prevalence study

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; DEPRESSION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; SELF CONCEPT; SEROCONVERSION; VIRUS LOAD;

EID: 0035675554     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(01)00611-3     Document Type: Article

References (28)

1. The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: Impact on medical, palliative care and quality of life outcomes
2. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men
3. Diagnosing depression in the hospitalised patient with chronic medical illness
4. Psychiatric morbidity in patients with HIV infection
5. Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool
6. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy
7. HIV-protease inhibitors
8. Cerebrospinal fluid HIV-1 RNA and drug concentration after treatment with lamivudine plus zidovudine or stavudine
9. The psychosocial impact of HIV infection in gay men, drug users and heterosexuals
10. HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir
11. Depression in the context of human immunodeficiency virus infection: Implication for treatment
12. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women
13. Depressive symptoms reduced in individuals with HIV/AIDS treated with antiretroviral therapy: A longitudinal study
14. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men
15. Psychopathology in male and female intravenous drug users with and without HIV infection
16. Depressive symptoms decline among persons on HIV protease inhibitors
17. Changes in depressive symptoms as AIDS develops
18. WHO Neuropsychiatric AIDS Study, cross-sectional phase. I. Study design and psychiatric findings
19. Depressive syndromes and symptoms in subjects with human immunodeficiency virus (HIV) infection
20. Psychiatric diagnosis before serological testing for the human immunodeficiency virus
21. Cerebral white matter changes in acquired immunodeficiency syndrome dementia: Alterations in the blood-brain barrier
22. The brain in AIDS: Central nervous system HIV-1 infection and AIDS dementia complex
23. Psychological effects of HAART: A 2-year study
24. Psychopathology in immunodeficiency virus infection: Lifetime and current assessment
25. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance
26. The structured clinical interview for DSMIII-R (SCID). I. History, rationale and description
27. Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection. II. Standardised clinical assessment of current and lifetime psychopathology
28. A self-rating depression scale